FLT3 and acute myeloid leukemia: FDA-approved treatments for FLT3 mutations include midostaurin (a first-generation inhibitor for FLT3-TKD and FLT3-ITD mutations) combined with chemotherapy [11]; gilteritinib (a second-generation inhibitor) as a single agent for relapsed or refractory AML [8]; and quizartinib (another second-generation inhibitor) in combination with chemotherapy for newly diagnosed FLT3-ITD AML patients [12].